-
Ionis sells part of the equity of Nocinaxen sodium and Pelacarsen for "a lot of cash", on the diversity of "financing channels
Time of Update: 2023-02-02
According to the agreement, until 2027, Royalty Pharma will receive 25 percent of Ionis' share of Spinraza's sales, rising to 45 percent after 2028, and 25 percent for another product, Pelacarsen.
-
Once troubled RNAi technology will eventually make a comeback
Time of Update: 2022-02-24
Dicerna's proprietary RNAi technology platform, called GalXCTM, silences disease genes in the liver .
RNAi technology specifically targets mRNA and modulates protein expression, and has great potential for silencing disease-related genes .
-
FDA grants orphan status for targeted drug tenagisib (RP6530) for skin T-cell lymphoma
Time of Update: 2020-06-11
recently, Rhizen Pharmaceutical son hasing ( FDA has granted the targeted drug tenagisib (RP6530) the status of an orphan drug for the treatment of skin T-cell lymphoma (CTCL) Prior to , the FDA
-
Phase III JADE Compare trial: JAK1 inhibitor abrocitinib treats atopic dermatitis with positive results
Time of Update: 2020-05-29
Pfizer Inc on Wednesday released a set of data showing that its research JAK1 inhibitor abrocitinib treated adults with moderate to severe asexual dermatitis in phase III JADE Compare trialreached
-
JAK inhibitor ruxolitinib treats severe COVID-19 patients: being evaluated
Time of Update: 2020-05-29
Incyte and Novartis Pharmaceuticals recently announced that they plan to launch a Phase III clinical trial (RUXCOVID study) to evaluate the effectiveness and safety of the combination of ruxolitini
-
Samsung bioepis has invested $1 billion to enter the U.S. generic drug market
Time of Update: 2015-08-24
Source: Biovalley, August 24, 2015, with the advent of the patent cliff, many biomedical companies lost patent protection for their best-selling drugs The biosimilars market has also become a new fiel
-
FDA approved afinitor for the treatment of noncancerous renal tumors caused by rare genetic diseases
Time of Update: 2012-04-27
Source: China Council for the promotion of medicine 2012-04-27 US Food and Drug Administration today approved the use of afinitor (everolimus) in the treatment of non cancer renal tumor (renal angiomy
-
Expert conflict rule: FDA officials disagree with pharmaceutical industry critics
Time of Update: 2012-02-06
Source: the impact of the shortage of drug experts in 2012-02-06 of the China Council for the promotion of drugs on the review process of the FDA expert panel is an issue under debate in the biopharma
